ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010
Hypertension in long-term survivors of pediatric hematopoietic cell transplantation.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Total Body Irradiation and Risk of Diabetes Mellitus; A Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2019Pooled it
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.Blood advances · 2020Trial
- Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation.International journal of radiation oncology, biology, physics · 2012Trial
- Long-term kidney side effects of allogeneic hematopoietic stem cell transplantation in children.Pediatric nephrology (Berlin, Germany) · 2025Article
- Pediatric Cancer Survivorship: A Review.Pediatric annals · 2025Review
- Hypertension in Childhood Cancer Survivors: Causes, Screening, and Management.Current hypertension reports · 2025Review
- Chronic Kidney Disease in Pediatric Recipients of Hematopoietic Stem Cell Transplantation in a 5-Year Observation-A Single Center Experience.International journal of pediatrics · 2025Article
- Intact NOX2 in T Cells Mediates Pregnancy-Induced Renal Damage in Dahl SS Rats.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2024Article
- Sex-Dependency of T Cell-Induced Salt-Sensitive Hypertension and Kidney Damage.Hypertension (Dallas, Tex. : 1979) · 2024Article
- A reappraisal of risk factors for hypertension after pediatric acute kidney injury.Pediatric nephrology (Berlin, Germany) · 2024Observational
- Ambulatory blood pressure monitoring in children and adolescents post-hematopoietic stem cell transplantation.Pediatric nephrology (Berlin, Germany) · 2024Article
- Transplant-associated thrombotic microangiopathy in pediatrics: incidence, risk factors, therapeutic options, and outcome based on data from a single center.Frontiers in oncology · 2024Article
- Etiology and outcomes of acute kidney disease in children: a cohort study.Clinical and experimental nephrology · 2023Article
- Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms.Clinical kidney journal · 2023Article
- Review of acute kidney injury and progression to chronic kidney disease in pediatric patients undergoing hematopoietic cell transplant.Frontiers in oncology · 2023Review
- Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.Pediatric nephrology (Berlin, Germany) · 2022Article
- Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation.European journal of pediatrics · 2022Article
- Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A retrospective study was conducted to determine risk factors for the development of hypertension (HTN) and to describe the prevalence among long-term survivors of pediatric hematopoietic cell transplant (HCT). Records of 689 pediatric patients who survived 5 years or more after HCT, from 1969 to 2004, were reviewed for development of HTN. In children, HTN was defined as either a systolic or diastolic pressure > or =95th percentile according to age, sex, and height. In adults, HTN was defined as systolic pressures > or =140 mmHg and/or diastolic pressures > or =90 mmHg in nondiabetic adults and systolic pressures > or =130 and/or diastolic pressures > or =80 in diabetic adults. Multivariate Cox regression models were used to estimate the hazard ratio (HR) of risk factors associated with HTN. All patients included were off immunosuppressive therapy. Patients had been treated with total body irradiation (TBI) (n = 482, 70%) or non-TBI regimens (n = 207, 30%) followed by autologous (n = 87), related (n = 484), or unrelated donor HCT (n = 118). Median follow-up was 16 (range: 5-36) years. HTN developed in 120 patients with a 30-year cumulative incidence of 36%. Risk factors associated with HTN were acute kidney injury (AKI; doubling of baseline creatinine by day 100 after HCT) (HR = 2.5; 95% confidence interval (CI) 1.7-3.7, P < .0001), TBI in the preparative regimen (HR = 2.1; 95% CI 1.3-3.3, P = .001), donor type (autologous HR = 2.4; 95% CI 1.3-4.4 and unrelated donor HR = 1.8; 95% CI 1.0-3.2, P = .01), obesity (HR = 4.0; 95% CI 2.3-6.8, P < .0001), diabetes (HR = 6.7; 95% CI 3.9-11.0, P < 0.0001), and history of growth hormone therapy (HR = 1.6; 95% CI 1.0-2.5, P = .05). Patients with a positive history of hepatitis C infection were less likely to develop HTN (HR = 0.5; 95% CI 0.3-0.9, P = .009). Prevalence of HTN was 15% overall and among survivors 11-17 years and 18-39 years old, the prevalence was 10% and 14% or triple and double that of the general U.S. population, respectively. Pediatric HCT survivors are more likely to develop HTN than the general population and should be monitored for HTN throughout adulthood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.